HK inno.N
inno.N continues to step up its efforts in innovation. responsibilities as an honorable corporate citizen. a leading global bio health company. ensures the highest quality. health products and beauty products. inno.N re-writes the history of rising to the challenge.
HK이노엔
바이오헬스기업 HK이노엔. 케이캡, 컨디션, 비원츠 등 전문의약품 및 헬스, 뷰티, 음료 제품 소개, 연구소개, ESG 등 정보 제공.
inno.N - Condition 解酒緩解宿醉果凍棒 (原味) 18g x 10 支盒 [平 …
AT10850, inno.N, Condition 解酒緩解宿醉果凍棒 (原味) 18g x 10 支盒 [平行進口], 尺碼 : 10, 天然草本製劑快速且有力地緩解宿醉 燒酒、葡萄酒、烈酒、啤酒 - 飲用前或飲用後各一棒 棒狀果凍，方便攜帶和食用-效果更快更強。
罗欣药业与韩国HK inno.N Corporation就引进替戈拉生注射剂产品 …
HK inno.N Corporation is a biotechnology and pharmaceutical company that is the process of applying to launch an IPO on the Korea Stock Exchange. Since inception in 1984, the firm has dominated the South Korean drug market with its lineup of prescription drugs for the treatment of gastrointestinal, kidney and circulatory aliments as well as ...
先为达生物与HK inno.N Corporation宣布就伊诺格鲁肽注射液的韩 …
2024年5月7日 · 伊诺格鲁肽注射液是一种具有cAMP偏向性的新型长效GLP-1激动剂，可用于治疗2型糖尿病、肥胖症和代谢功能障碍相关的脂肪性肝炎（MASH）。 根据协议，先为达生物将获得首付款， 并将有资格获得高达5600万美元的研发、注册和商业化相关的里程碑付款，以及产品商业化后高达两位数字的销售额提成。 HK inno.N Corporation将获得在韩国开发和商业化伊诺格鲁肽注射液的独家权益。 先为达生物仍将保留在全球所有其他市场开发和商业化伊诺格鲁肽注射 …
HK inno.N becomes largest shareholder of Japan’s RaQualia to …
1 天前 · HK inno.N has become the largest shareholder of Japan’s RaQualia Pharma by acquiring a 10.61 percent stake, aiming to strengthen R&D ties and boost the Japanese launch of its GERD drug, K-CAB.
HK inno.N moves topical JAK inhibitor into phase 2 for atopic ...
2025年3月17日 · HK inno.N has secured approval from the Ministry of Food and Drug Safety for a phase 2 trial of IN-115314, a topical janus kinases (JAK-1) inhibitor targeting mild to moderate atopic dermatitis.
5600万美元！先为达GLP-1“出海”韩国 - 煜森资本
2024年5月9日 · 伊诺格鲁肽注射液是一种具有cAMP偏向性的新型长效GLP-1激动剂，经优化提高生物活性，降低生产成本，可满足每周一次给药。 糖尿病Ⅱ期临床试验数据显示，治疗20周后，伊诺格鲁肽注射液1.2mg组的糖化血红蛋白（HbA1c）相对基线改变值达2.4%；中国超重和肥胖症Ⅰc/Ⅱa期临床试验中期数据显示，治疗14周后，伊诺格鲁肽注射液1.8mg组的受试者平均体重下降了9.6%（8.3公斤）；国际多中心肥胖症Ⅱb期临床试验数据显示，治疗18周后，伊诺格鲁肽 …
HK inno.N speeds up developing homegrown obesity drug
2025年1月2日 · HK inno.N has submitted an IND (investigative new drug) plan for a phase 3 clinical trial of a GLP-1 receptor agonist (GLP-1 RA) for treating obesity, drawing the industry’s interest. The company said Tuesday that it has presented a phase 3 IND for its obesity treatment candidate IN-B00009 to the Ministry of Food and Drug Safety.
195940 Stock Price Quote | Morningstar
See the latest HK Inno N Corp stock price (195940:XKRX), related news, valuation, dividends and more to help you make your investing decisions.
- 某些结果已被删除